STOCK TITAN

Rein Therapeutics, Inc. reported $0 in revenue and a $49.9M net loss for fiscal 2025. See the full RNTX financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

Rein Therapeutics to Present at Upcoming September Investor Conferences

Rein Therapeutics will webcast two New York investor conference presentations in mid-September 2026 for online and replay viewing.

(Moderate)
(Very Positive)
Tags

Rein Therapeutics (RNTX) will present at two investor conferences in September 2026. President and CEO Brian Windsor is scheduled to speak at the 2026 Cantor Global Healthcare Conference on September 11, 2026, at 8:00 a.m. ET in New York, NY, and at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m. ET, also in New York.

A live webcast of both presentations will be available through the Investors section of the company’s website, with archived replays accessible for approximately 90 days after the events.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

Market Context

Rein’s August 14 earnings report coincided with a 2.35% 24-hour gain, adding a positive historical r...
Analysis

Rein’s August 14 earnings report coincided with a 2.35% 24-hour gain, adding a positive historical reference for scheduled investor events. The Nasdaq compliance notice below $1.00 remains a material risk to monitor.

Key Figures

Cantor conference date: September 11, 2026 Cantor presentation time: 8:00 a.m. ET Wainwright conference date: September 14, 2026 +2 more
5 metrics
Cantor conference date September 11, 2026 2026 Cantor Global Healthcare Conference
Cantor presentation time 8:00 a.m. ET September 11, 2026
Wainwright conference date September 14, 2026 H.C. Wainwright 28th Annual Global Investment Conference
Wainwright presentation time 11:00 a.m. ET September 14, 2026
Replay availability approximately 90 days Following the conferences

Historical Context

5 past events · Latest: Aug 20 (Positive)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Aug 20 Fast Track designation Positive +0.2% FDA Fast Track designation for LTI-03 in idiopathic pulmonary fibrosis
Aug 14 2Q26 earnings report Positive +2.4% Second-quarter results included financing, trial progress, and operating expense updates
Aug 04 Clinical data publication Positive +2.4% Peer-reviewed first-in-human LTI-03 data were published in Nature Communications
Jul 21 Phase 2 enrollment Positive +6.0% RENEW Phase 2 trial began enrollment across all five planned countries
Jun 11 Trial expansion Positive +0.6% First patient randomized in United Kingdom, expanding RENEW trial enrollment footprint

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The five recent positive announcements were followed by positive 24-hour reactions ranging from 0.2% to 6.02%.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, President and Chief Executive Officer of Rein Therapeutics, will present at the following investor conferences in September.

2026 Cantor Global Healthcare Conference
Date & Time: Friday, September 11, 2026, at 8:00 a.m. ET
Location: New York, NY

H.C. Wainwright 28th Annual Global Investment Conference
Date: Monday, September 14, 2026 at 11:00 a.m. ET
Location: New York, NY

A live webcast of the presentations may be accessed via the Investors section of the Rein website at ir.reintx.com. An archived replay of the events will be available on the website for approximately 90 days following the conference.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein’s lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 has received both Orphan Drug and Fast Track designations in the U.S.

Investor Contact

IR@ReinTx.com


FAQ

When will Rein Therapeutics (RNTX) present at the 2026 Cantor Global Healthcare Conference?

Rein Therapeutics is scheduled to present at the 2026 Cantor Global Healthcare Conference on Friday, September 11, 2026, at 8:00 a.m. ET in New York, NY. The presentation will also be available via live webcast on the company’s investor website.

What is the date and time of Rein Therapeutics (RNTX) presentation at the H.C. Wainwright 28th Annual Global Investment Conference?

Rein Therapeutics plans to present at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026, at 11:00 a.m. ET in New York, NY, with the session accessible through a live webcast on its investor site.

Who will present for Rein Therapeutics (RNTX) at the September 2026 investor conferences?

Brian Windsor, President and Chief Executive Officer of Rein Therapeutics, will present at both the 2026 Cantor Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference in New York.

How can investors access the Rein Therapeutics (RNTX) webcasts for the September 2026 conferences?

Investors can access live webcasts of Rein Therapeutics’ September 2026 conference presentations via the Investors section of the company’s website at ir.reintx.com. An archived replay of the events will be available on the site for approximately 90 days.

Will replays of the Rein Therapeutics (RNTX) September 2026 investor presentations be available?

Yes. An archived replay of Rein Therapeutics’ investor conference presentations will be available on the company’s investor website for approximately 90 days following the conferences.